After Hours
$
217.20
Change
+0.27 +0.12%
Volume
Volume 269,157
May 26, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Previous close
$ 217.46
$ 216.93
Change
-0.53 -0.24%
Day low
Day high
$214.48
$218.48

52 week low
52 week high
$214.48
$296.67

Market cap
$115.91B
Average volume
2.23M
P/E ratio
14.74
Rev. per Employee
$1.03M
EPS
14.71
Dividend
2.13
Div yield
3.93%
Ex dividend date
5/17/23
MarketWatch News on AMGN
-
How Nvidia Can Become First $1 Trillion Chip Stock
- Ben Levisohn
-
9 Cheap Healthcare Stocks to Consider
- Josh Nathan-Kazis
-
FTC sues to block Amgen’s acquisition of Horizon Therapeutics
- Eleanor Laise
-
FTC Sues to Block Amgen's Acquisition of Horizon
- Josh Nathan-Kazis
-
FTC sues to block Amgen’s acquisition of Horizon Therapeutics
- Eleanor Laise
-
Here’s the big thing holding up the stock market, says Bank of America
- Barbara Kollmeyer
-
Walgreens Boots, Amgen share losses lead Dow's 84-point fall
- MarketWatch Automation
-
Weight-Loss Drugs Will Be Blockbusters. Here’s the Stock to Buy.
- Josh Nathan-Kazis
-
Walgreens Boots, Amgen share losses lead Dow's 85-point fall
- MarketWatch Automation
-
Alphabet, Meta Platforms, Amazon.com and More
- Nicholas Jasinski
-
China’s Consumer-Led Growth Looks More Like a Bounce, Not a Recovery
- Reshma Kapadia
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Analysts’ Latest Recommendations on Mylan
- MarketRealist.com
-
Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
- MarketRealist.com
Other News on AMGN
-
Elizabeth Warren and the FTC Are the Least of Amgen’s Problems
- The Wall Street Journal Interactive Edition
-
Walmart, Tesla, Micron: Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
Antitrust Gone Wild Against Amgen
- The Wall Street Journal Interactive Edition
-
Sanofi Wins Supreme Court Patent Dispute With Amgen
- The Wall Street Journal Interactive Edition
-
FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
- The Wall Street Journal Interactive Edition
-
FTC’s Amgen Activism Will Spare Smaller Biotechs
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
Merck Struggles to Expand Its Cancer-Drug Juggernaut
- The Wall Street Journal Interactive Edition
-
How to Tell Biotech’s Likely Winners From Losers
- The Wall Street Journal Interactive Edition
-
Merck to Buy Prometheus Biosciences
- The Wall Street Journal Interactive Edition
-
Amgen Seeks to Monopolize Nature
- The Wall Street Journal Interactive Edition
-
Eli Lilly Is Priced for Perfection in the Obesity Market
- The Wall Street Journal Interactive Edition
-
Pfizer Overpays for Seagen, but Who’s Counting
- The Wall Street Journal Interactive Edition
-
New Drugs for Cancer, Rare Disease Can Cost Over $20,000 a Month
- The Wall Street Journal Interactive Edition
-
Why Some Investors Are Still Waiting for Discounts on Corporate Bonds
- The Wall Street Journal Interactive Edition
-
Top 5 4th Quarter Trades of Palouse Capital Management, Inc.
- GuruFocus.com
-
Top 5 4th Quarter Trades of BERKSHIRE ASSET MANAGEMENT LLC/PA
- GuruFocus.com
-
FEDERATED HERMES, INC. Buys 1, Sells 4 in 4th Quarter
- GuruFocus.com
-
Palouse Capital Management, Inc. Buys 2, Sells 3 in 4th Quarter
- GuruFocus.com
-
Top 5 4th Quarter Trades of Compagnie Lombard Odier SCmA
- GuruFocus.com
- Loading more headlines...
Press Releases on AMGN
-
- Newsfile Corp
-
- Newsfile Corp
-
- Newsfile Corp
-
Amgen Shareholder Action Reminder
- Newsfile Corp
-
- Newsfile Corp
-
Amgen Shareholder Action Reminder
- Newsfile Corp
-
- Newsfile Corp
-
Amgen Shareholder Action Reminder
- Newsfile Corp
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com